Investigational drug · Phase 3
RC148
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
10
Any phase or sponsor naming "RC148"
First trial start
2023
Sep 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RC148", any sponsor or status.
Conditions studied
As listed on its trial records.
- Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
- Solid Tumor
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Breast Cancer
- Colorectal (Colon or Rectal) Cancer
- Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
- Non-Small Cell Lung Cancer
- Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RC148" as an intervention, largest first.
- RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ AdenocarcinomaPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07935369 · 680 participants (planned) · Start Nov 2026 · Primary completion Apr 30, 2030
Drug: RC118(Dose 1) plus RC148(Dose 1); RC118(Dose 1) plus RC148(Dose 2) and 4 more · For: Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China; Shanghai, China
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)Pivotal-lookingRecruiting
RemeGen Co., Ltd.Industry
NCT07416474 · 574 participants (planned) · Start Apr 3, 2026 · Primary completion Dec 31, 2027
Drug: RC148 plus Carboplatin and Paclitaxel; Tislelizumab plus Carboplatin and Paclitaxel · For: Non-Small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 78 sites in all
- Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsPivotal-lookingRecruiting
RemeGen Co., Ltd.Industry
NCT07829549 · 540 participants (planned) · Start Oct 10, 2026 · Primary completion Apr 2031
Drug: RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection; Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection · For: Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
Sites: Hunan, China
- Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal CancerPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07895355 · 412 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: RC148 plus Telisotuzumab adizutecan; RC148 plus Telisotuzumab adizutecan and 4 more · For: Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Sites: Guangdong, China
RemeGen Co., Ltd.Industry
NCT06016062 · 221 participants (planned) · Start Sep 14, 2023 · Primary completion Dec 31, 2025
Drug: RC148 Monotherapy; RC148+docetaxel Combination Therapy and 3 more · For: Solid Tumor
Sites: Anhui, China; Beijing, China; Changchun, China · 31 sites in all
- Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung CancerPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07874282 · 200 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: Telisotuzumab adizutecan plus RC148(ABBV-1480); Telisotuzumab adizutecan plus RC148(ABBV-1480) · For: Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
Sites: Shanghai, China
- A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCPivotal-lookingActive, not recruiting
RemeGen Co., Ltd.Industry
NCT06883630 · 121 participants · Start Mar 13, 2025 · Primary completion Aug 31, 2026
Drug: RC148 plus Carboplatin and Paclitaxel/pemetrexed; RC148 · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Foshan, China; Guangzhou, China · 24 sites in all
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal CancerPivotal-lookingRecruiting
RemeGen Co., Ltd.Industry
NCT07462143 · 80 participants (planned) · Start May 12, 2026 · Primary completion May 12, 2027
Drug: RC148 (Dose 1) plus Capecitabine and Oxaliplatin; RC148 (Dose 2) plus Capecitabine and Oxaliplatin · For: Colorectal (Colon or Rectal) Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 19 sites in all
- A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsStatus unknown
RemeGen Co., Ltd.Industry
NCT06038396 · 48 participants (planned) · Start Aug 3, 2023 · Primary completion Feb 28, 2026
Drug: RC118; Toripalimab and 1 more · For: Advanced Solid Tumor
Sites: Fuzhou, China; Xiamen, China; Wuwei, China · 18 sites in all
RemeGen Co., Ltd.Industry
NCT06642545 · 40 participants (planned) · Start Feb 10, 2025 · Primary completion Oct 1, 2026
Drug: Disitamab Vedotin; RC148 and 2 more · For: Breast Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.